1. Home
  2. IIF vs CHRS Comparison

IIF vs CHRS Comparison

Compare IIF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley India Investment Fund Inc.

IIF

Morgan Stanley India Investment Fund Inc.

HOLD

Current Price

$22.95

Market Cap

210.5M

Sector

Finance

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.41

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIF
CHRS
Founded
1993
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.5M
209.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
IIF
CHRS
Price
$22.95
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
33.3K
700.5K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
13.94%
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.83
$0.81
52 Week High
$27.99
$2.62

Technical Indicators

Market Signals
Indicator
IIF
CHRS
Relative Strength Index (RSI) 57.41 45.98
Support Level $22.01 $1.38
Resistance Level $23.66 $1.74
Average True Range (ATR) 0.42 0.06
MACD -0.01 0.00
Stochastic Oscillator 73.11 47.63

Price Performance

Historical Comparison
IIF
CHRS

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: